Helen J Mackay (Helen MacKay)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Endometrial Cancer

Oxidative Stress

Placebo Controlled

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Helen J Mackay, Ítalo Fernandes
Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls. Cancer 130 (19) (2024)
Helen J Mackay, Ítalo Fernandes
Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls. Cancer (2024)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor J Backes, Elizabeth Swisher, Matthew Powell, Helen J Mackay
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 130 (8) (2023)
Helen J Mackay, Elise C Kohn
Intraperitoneal chemotherapy: Hot, timely, and relevant? Cancer 126 (24) (2020)